Last reviewed 2026-06-03 · How we verify

ClōSYS® Unflavored Rinse

Rowpar Pharmaceuticals, Inc. · Phase 1 active Small molecule ✓ Verified Jun 2026

ClōSYS® Unflavored Rinse is a Small molecule drug developed by Rowpar Pharmaceuticals, Inc.. It is currently in Phase 1 development. Also known as: Mouth rinse.

ClōSYS Unflavored Rinse is a small molecule oral rinse used to control oral malodor, as indicated by a clinical trial on ClinicalTrials.gov. The exact mechanism of action of ClōSYS Unflavored Rinse is currently unknown, according to ChEMBL.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ClōSYS® Unflavored Rinse
Also known as	Mouth rinse
Sponsor	Rowpar Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ClōSYS® Unflavored Rinse CI brief — competitive landscape report
ClōSYS® Unflavored Rinse updates RSS · CI watch RSS
Rowpar Pharmaceuticals, Inc. portfolio CI

Frequently asked questions about ClōSYS® Unflavored Rinse

What is ClōSYS® Unflavored Rinse?

ClōSYS® Unflavored Rinse is a Small molecule drug developed by Rowpar Pharmaceuticals, Inc..

Who makes ClōSYS® Unflavored Rinse?

ClōSYS® Unflavored Rinse is developed by Rowpar Pharmaceuticals, Inc. (see full Rowpar Pharmaceuticals, Inc. pipeline at /company/rowpar-pharmaceuticals-inc).

Is ClōSYS® Unflavored Rinse also known as anything else?

ClōSYS® Unflavored Rinse is also known as Mouth rinse.

What development phase is ClōSYS® Unflavored Rinse in?

ClōSYS® Unflavored Rinse is in Phase 1.

Manufacturer: Rowpar Pharmaceuticals, Inc. — full pipeline
Also known as: Mouth rinse

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing